Discounted Cash Flow (DCF) Analysis Levered
Karyopharm Therapeutics Inc. (KPTI)
$1.285
+0.07 (+5.33%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 30.34 | 40.89 | 108.08 | 209.82 | 157.07 | 262.35 | 438.19 | 731.89 | 1,222.43 | 2,041.76 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -159.12 | -190.82 | -160.23 | -107.12 | -149.55 | -674.59 | -1,126.74 | -1,881.92 | -3,143.27 | -5,250.03 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -2.36 | -0.21 | -0.15 | -5.71 | -0.12 | -5.89 | -9.84 | -16.43 | -27.44 | -45.84 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -161.48 | -191.03 | -160.38 | -112.83 | -149.67 | -680.48 | -1,136.57 | -1,898.35 | -3,170.72 | -5,295.87 |
Weighted Average Cost Of Capital
| Share price | $ 1.285 |
|---|---|
| Beta | -0.012 |
| Diluted Shares Outstanding | 81.87 |
| Cost of Debt | |
| Tax Rate | -0.22 |
| After-tax Cost of Debt | 14.45% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 4.745 |
| Total Debt | 172.98 |
| Total Equity | 105.20 |
| Total Capital | 278.18 |
| Debt Weighting | 62.18 |
| Equity Weighting | 37.82 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 30.34 | 40.89 | 108.08 | 209.82 | 157.07 | 262.35 | 438.19 | 731.89 | 1,222.43 | 2,041.76 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -159.12 | -190.82 | -160.23 | -107.12 | -149.55 | -674.59 | -1,126.74 | -1,881.92 | -3,143.27 | -5,250.03 |
| Capital Expenditure | -2.36 | -0.21 | -0.15 | -5.71 | -0.12 | -5.89 | -9.84 | -16.43 | -27.44 | -45.84 |
| Free Cash Flow | -161.48 | -191.03 | -160.38 | -112.83 | -149.67 | -680.48 | -1,136.57 | -1,898.35 | -3,170.72 | -5,295.87 |
| WACC | ||||||||||
| PV LFCF | -614.27 | -926.14 | -1,396.35 | -2,105.29 | -3,174.17 | |||||
| SUM PV LFCF | -8,216.21 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 10.78 |
| Free cash flow (t + 1) | -5,401.79 |
| Terminal Value | -61,523.78 |
| Present Value of Terminal Value | -36,875.35 |
Intrinsic Value
| Enterprise Value | -45,091.56 |
|---|---|
| Net Debt | 37.79 |
| Equity Value | -45,129.35 |
| Shares Outstanding | 81.87 |
| Equity Value Per Share | -551.23 |